Medical Sciences Divisional Office
University of Oxford
Level 3, John Radcliffe Hospital
Oxford OX3 9DU
Head of Medical Sciences Division
The Head of Division is responsible for maintaining and further developing the international reputation of Medical Sciences in both research and teaching. He provides vision and leadership across all aspects of the Division's activities including divisional research strategy, educational policy and standards, the recruitment and retention of outstanding academics, relationships with external funding agencies, interactions with local NHS Foundation Trusts, fundraising, improving diversity and equality, and the use of resources. He works closely with the heads of the 16 departments within the Division and the other University academic divisions to foster strong interdisciplinary links across the spectrum of academic activity and with the colleges to help maintain excellence in teaching for undergraduate and graduate courses.
The Head of Division is a member of University Council and its major committees, which are responsible for determining overall university strategy.
Prior to being appointed as the Head of the Medical Sciences Division, Professor Screaton was Dean of the Faculty of Medicine, Imperial College.
Guillain-Barré Syndrome Following Zika Virus Infection Is Associated With a Diverse Spectrum of Peripheral Nerve Reactive Antibodies.
Davies AJ. et al, (2023), Neurology(R) neuroimmunology & neuroinflammation, 10
A delicate balance between antibody evasion and ACE2 affinity for Omicron BA.2.75.
Huo J. et al, (2022), Cell reports
Antigenic characterization of SARS-CoV-2 Omicron subvariant BA.4.6.
Dijokaite-Guraliuc A. et al, (2022), Cell discovery, 8
CryoEM structures of the multimeric secreted NS1, a major factor for dengue hemorrhagic fever.
Shu B. et al, (2022), Nature communications, 13
Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial
Shaw RH. et al, (2022), The Lancet Respiratory Medicine, 10, 1049 - 1060